Key Takeaways
- A brutal Q4, and Q1 will be worse: Margins collapsed 800–900 bps YoY as raw material, energy and freight costs spiked after the Ukraine war, while demand softened. Management expects Q1 FY23 to be even more subdued and mark the bottom.
- The pass-through lag is the core problem: Even CDMO contracts with cost pass-through clauses carry a three- to six-month lag, so Hikal absorbed the full force of input cost inflation in Q4. The recovery timeline depends entirely on how fast those price increases can be pushed to customers.
- Pharma demand hit by destocking, not structural loss: Generic API demand fell as customers liquidated inventory built up during the pandemic. Management chose not to sell at low prices to fill that inventory, and confirmed no customers or contracts were lost.
- Crop Protection is the nearer-term growth engine: A new fungicide plant commissions by end-CY2022, with a combined potential of ₹400–500 crore from two fungicides. Crop assets commercialize in 6–9 months, versus 18–24 months for pharma.
- What to watch next quarter: Whether Q1 truly marks the margin bottom, the pace of price pass-through in Q2, and the Taloja plant reopening timeline after the MPCB closure notice.
The Margin Shock: What Happened and When It Recovers
- Input costs surged across the board: After Russia invaded Ukraine, crude oil spiked, energy costs nearly doubled, raw material prices rose 40–60%, and solvent prices jumped ~40%. The disruption was global, not just China-driven, compounded by COVID lockdowns.
- Pass-through contracts did not protect Q4: Even where cost pass-through mechanisms exist, the typical three- to six-month reset window meant Hikal bore the full cost increase in the quarter. Discussions with customers are underway, with impact expected in FY23.
- Pharma margins hit 13.4% for the full year: Q4 was described as "probably the worst" on the pharma side. The company chose not to sell at very low prices and build inventory at customers' end, preferring to be "slow and steady."
- Crop Protection margins also at a trough: Sequential fall driven by the same supply chain disruption, plus difficulty passing costs to price. Margins were down 800–900 bps YoY in Q4, though the first nine months of FY22 had been strong.
- The recovery path is Q1 bottom, then stepwise improvement: Q1 FY23 will be more subdued than Q4, then improvement in Q2, with increases in Q3 and Q4. Management is hopeful of returning to normal margins in FY24, but external circumstances are beyond its control.
- Cost improvement programs are underway: Initiatives include strategic vendor relationships with long-term contracts, de-risking supply chain from China, backward integration, manufacturing excellence (yield improvement, solvent recovery), and a shift to renewable energy and biomass. These are expected to support margin recovery in H2 FY23.
Anish Swadi: "Q1 overall for the company as we look at it will certainly be more subdued than Q4. ... Q1 will probably bottom out and then you will have an improvement in Q2 and then you will see an increase in Q3 and Q4 going forward."
Pharma: Destocking Masks Underlying CDMO Momentum
- Revenue grew just 6.6% YoY in FY22: The slowdown was driven by generic API destocking after pandemic-era inventory build-up, not by loss of business. CDMO demand remains buoyant, and the base business is expected to return to prior levels from Q2 onwards.
- CDMO mix dipped on inventory corrections: CDMO as a percentage of pharma sales fell from 54% to 44% between FY20 and FY22 as customers corrected excess inventory. Two KSMs for new drugs and one intermediate opportunity were converted with global innovators in FY22.
- Animal Health is a multi-year build: Process development work has commenced for several active ingredients under a multi-year project with a global innovator. The dedicated plant is expected to commission by FY23, with revenue accrual from FY24. Wave I and II products are in the pipeline, with Wave III and IV potentially to follow.
- New product launches planned: Four to five products are targeted for launch in FY23 from a pipeline of ten-plus products in development. DMF filings are expected to accelerate from 2–3 per year to 4–5 per year as R&D investment increases.
- Segment growth guided at 12–15% from FY24: FY23 is uncertain due to external issues, but management expects pharma to return to that growth range once conditions normalize. Gliptins and Gliflozins (anti-diabetic) are expected to generate significant commercial sales from FY24 as patents expire.
Manoj Mehrotra: "We would also not like to really sell at very low prices and build up inventory at customers' end. So, it's better to be a little slow and steady and make sure that the cost is passed on over a period of time."
Crop Protection: Near-Term Growth Engine with Faster Asset Turns
- Revenue grew 23% YoY in FY22: Growth came from higher demand from leading CDMO customers and new contracts with key U.S. and Japanese customers. Sales of own products slowed due to raw material availability issues.
- A fungicide-led growth story: One fungicide plant is to be commissioned by end of Q3 CY2022 (end of FY23), with revenue starting by end of FY23. A second fungicide is planned, with combined potential of ₹400–500 crore. Two to three more products are expected in the next one to two years.
- Pipeline is filling: About six products are in the pipeline at proof-of-concept stage, moving toward semi-commercial stages. Inquiries are coming from both existing and new customers, especially from the U.S. and Japan.
- Faster commercialization cycle: Crop protection assets typically take 6–9 months to commercialize after project completion, versus 18–24 months for pharma. This means nearer-term revenue visibility from the CAPEX currently underway.
- Margin recovery also hinges on pass-through: Management is confident that from Q2 it will be able to pass cost impacts into prices, though a lag is expected.
Regulatory Overhang: Taloja Closure and Sachin Incident
- Taloja plant received an MPCB closure notice following the January 6, 2022 Sachin GIDC incident, where a tanker allegedly carrying byproduct from Hikal's Taloja factory was involved. Management stated the tanker reported as allegedly disposing chemicals was not the same tanker that left company premises, and all documentary evidence has been provided.
- Legal position appears strong: The Gujarat High Court order recognized the non-existent role of Hikal and its employees. No Hikal employees are in judicial custody; all have resumed work. The matter remains subjudice, and Hikal claims a "very strong legal position." A writ petition on the Taloja closure is to be heard in the coming week.
- Reopening will be gradual: Upon reopening, Hikal will begin executing a pending order book built up over the quarter, but will have to gradually ramp up scale of operations, which could have some short-term impact on the crop protection business.
- ESG and audit upgrades underway: A reputed audit firm (Mahajan & Aibara) has been onboarded for internal audit, and a reputed ESG firm has been partnered for third-party audits across the entire plant network.
Strategy and CAPEX: Consolidation Before Acceleration
- FY23 framed as a year of "necessary slowdown and consolidation": Management is using the year to prepare for future accelerated growth, with market headwinds expected to continue.
- CAPEX is being pruned to essentials: FY23 CAPEX is guided at ₹250–270 crore cash outflow, focused on "absolutely necessary" and customer-backed projects. "Good-to-have" CAPEX has been deferred to H2 FY23.
- Assets are mostly contract-backed: CAPEX is largely backed by contracts and/or products in the pipeline. Management is hopeful that from end of Q2 onwards there will be a "resurrection in terms of the business."
- Project Pinnacle launched: A global consultant has been onboarded to identify strategic direction for products, partners, and technologies, while bolstering R&D and manufacturing capabilities.
- Long-term margin ambition is ~20% consolidated: Annual margin improvement of 50–100 bps is expected from FY24 onwards. FY25 revenue of around ₹3,000 crore was described as "possible." Both divisions are expected to grow at 15%, with crop protection able to scale faster.
Anish Swadi: "We expect FY23 to be a year of necessary slowdown and consolidation to prepare us for future accelerated growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin bottom | Q1 FY23 will be more subdued than Q4 FY22 and "probably bottom out" | Q1 FY23 |
| Margin recovery path | Stepwise improvement Q2 through Q4 FY23; hopeful of normal margins | FY24 |
| Pharma price pass-through | Impact of customer price discussions to be seen | FY23 |
| Pharma base business recovery | CDMO base business to return to prior levels | From Q2 FY23 |
| Pharma new product launches | Four to five products from a pipeline of ten-plus | FY23 |
| Animal Health plant commissioning | Plant complete, revenue accrual begins | FY23 commissioning; FY24 revenue |
| Fungicide plant commissioning | First fungicide plant complete, revenue starts | End of Q3 CY2022; revenue by end FY23 |
| Second fungicide launch | Combined potential of ₹400–500 crore from two fungicides | Not specified |
| CAPEX cash outflow | ₹250–270 crore, focused on essential and customer-backed projects | FY23 |
| Long-term segment growth | Both divisions to grow at 15% | From FY24 onwards |
| Long-term margin target | ~20% consolidated, with 50–100 bps annual improvement | From FY24 onwards |
| FY25 revenue potential | Around ₹3,000 crore described as "possible" | FY25 |
| Taloja plant reopening | Pending order book execution begins; gradual ramp-up | Upon MPCB clearance |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Consolidated total revenue | ₹1,943 cr (FY22), +13% YoY |
| Profit before tax | ₹341 cr (FY22), +5% YoY |
| EBITDA margin | 17.6% (FY22); 9M FY22 was 19.6% vs 18% in 9M FY21 |
| Pharma revenue | ₹1,130 cr (FY22), +6.6% YoY |
| Pharma EBIT margin | 13.4% (FY22) |
| Crop protection revenue | ₹813 cr (FY22), +23% YoY |
| Crop protection EBIT margin | 14.3% (FY22) |
| Debt-to-equity ratio | 0.59x, improved from 0.61x in FY21 and 0.73x the year prior |
| Average borrowing cost | 6.15% blended rate (Mar 2022), down from 6.99% in Mar 2021 |
| Return on equity | 16.2% (FY22), improved from 15.2% in FY21 |
| Total dividend | 80% or ₹1.60 per share (FY22) |
| Total debt | ₹675 cr (Mar 2022): ₹273 cr working capital, ₹402 cr long-term |
| FY23 expected capex cash outflow | ₹250–275 cr |
| FY23 expected capex capitalization | ~₹400 cr |
| Taloja facility revenue contribution | ₹260–280 cr |